MDxHealth SA
Advanced molecular diagnostics for urologic diseases, focusing on personalized prostate cancer care.
MDXH | BR
Overview
Corporate Details
- ISIN(s):
- BE0974461940
- LEI:
- 549300J3MG9F9B5FY646
- Country:
- Belgium
- Address:
- Rue d'Abhooz 31, 4040 Herstal
- Website:
- https://mdxhealth.com/
- Sector:
- Human health and social work activities
- Industry:
- Other human health activities
Description
MDxHealth SA is a commercial-stage precision diagnostics company focused on providing actionable molecular information for the diagnosis and treatment of urologic diseases, with a primary emphasis on prostate cancer. The company develops and commercializes advanced diagnostic tests based on proprietary genetic, epigenetic, and other molecular technologies. These solutions, such as the Genomic Prostate Score, are designed to help clinicians personalize patient care by better identifying aggressive disease and informing crucial treatment decisions. By concentrating on the urology market, MDxHealth delivers clinically validated and cost-effective tools to improve risk stratification and patient outcomes.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2023-12-18 07:00 |
Delisting Announcement
MDXH PR EN.pdf
|
English | 241.9 KB | ||
| 2023-12-18 07:00 |
Delisting Announcement
MDXH PR FR.pdf
|
French | 236.7 KB | ||
| 2023-11-27 07:00 |
Delisting Announcement
PR 2023 10 27 EN.pdf
|
English | 249.4 KB | ||
| 2023-11-27 07:00 |
Delisting Announcement
PR 2023 10 27 FR.pdf
|
French | 241.5 KB | ||
| 2023-11-13 22:00 |
Share Issue/Capital Change
MDxHealth - New Denominator (EN).pdf
|
English | 249.5 KB | ||
| 2023-11-13 22:00 |
Share Issue/Capital Change
MDxHealth - New Denominator (FR).pdf
|
French | 250.1 KB | ||
| 2023-11-08 22:00 |
Earnings Release
MDxHealth 3Q23 FINAL EN.pdf
|
English | 288.9 KB | ||
| 2023-11-08 22:00 |
Earnings Release
MDxHealth 3Q23 FINAL FR.pdf
|
French | 299.0 KB | ||
| 2023-11-06 07:00 |
AGM Information
EGM results and process (FR).pdf
|
French | 261.5 KB | ||
| 2023-11-06 07:00 |
Share Issue/Capital Change
EGM results and process (ENG).pdf
|
English | 259.2 KB | ||
| 2023-11-06 07:00 |
Pre-Annual General Meeting Information
EGM Deed (3 November 2023).pdf
|
French | 4.3 MB | ||
| 2023-11-06 07:00 |
Delisting Announcement
EGM results and process (ENG).pdf
|
English | 259.2 KB | ||
| 2023-11-06 07:00 |
AGM Information
EGM results and process (FR).pdf
|
French | 261.5 KB | ||
| 2023-10-20 22:00 |
Share Issue/Capital Change
MDxHealth - Press Release (ENG).pdf
|
English | 210.7 KB | ||
| 2023-10-20 22:00 |
Share Issue/Capital Change
MDxHealth - Press Release (FR).pdf
|
French | 212.8 KB |
Automate Your Workflow. Get a real-time feed of all MDxHealth SA filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for MDxHealth SA
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for MDxHealth SA via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2023-09-11 | KALFUS RON | Executive member | Buy | 400,000 | 116,000.00 EUR |
| 2023-09-10 | Sollee Joseph | Executive member | Buy | 200,000 | 58,000.00 EUR |
| 2022-09-26 | KALFUS RON | Executive member | Buy | 200,000 | 136,800.00 EUR |
| 2022-09-23 | Sollee Joseph | Executive member | Buy | 200,000 | 136,800.00 EUR |
| 2021-01-26 | SLAGMULDER REGINE | Board | Buy | 78,091 | 79,653.00 EUR |
| 2021-01-25 | SLAGMULDER REGINE | Board | Buy | 212,182 | 216,298.00 EUR |
| 2020-09-21 | SLAGMULDER REGINE | Board | Buy | 52,000 | 37,824.80 EUR |
| 2020-09-18 | SLAGMULDER REGINE | Board | Buy | 10,000 | 7,223.00 EUR |
| 2020-09-17 | SLAGMULDER REGINE | Board | Buy | 4,000 | 2,860.40 EUR |
| 2020-09-16 | SLAGMULDER REGINE | Board | Buy | 7,000 | 4,988.20 EUR |
Peer Companies
